FD
Pacira Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EXPAREL® (bupivacaine liposome) | Acute Post-Surgical Pain (Pediatric 0 to < 6 years) | Phase 3 |
| PCRX-201 (enekinragene inzadenovec) | Osteoarthritis of the Knee (OAK) | Phase 1 |
| PCRX-2002 | Post-Surgical Pain | Not Specified (Likely Preclinical/Phase 1) |
| ZILRETTA® (triamcinolone acetonide) | Shoulder Osteoarthritis (OA) | Phase 3 |
| iovera® | Spasticity | Phase 2 (or development for new indication) |
Leadership Team at Pacira Biosciences
BT
Brendan Teehan
Chief Commercial Officer
KW
Kristen Williams, Esq
Chief Administrative Officer & Secretary
JS
Jonathan Slonin, MD
Chief Medical Officer
SC
Shawn Cross
Chief Financial Officer
AM
Anthony Molloy III, Esq.
Chief Legal & Compliance Officer
CY
Christopher Young
Chief Manufacturing Officer
KC
Krys Corbett
Chief Business Officer
LB
Laura Brege
Independent Board Chair
MB
Marcelo Bigal, MD, PhD
President and CEO of Ventus Therapeutics
AC
Abraham Ceesay
CEO Rapport Therapeutics